Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer. Andrew joins Medicus with over three decades of experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Andrew, most recently, was the Chief Executive of SR Asset Management (SRAM) until its sale in 2024. Before joining SRAM...
2025-06-23 7:30 AM EDT
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention.Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston Convention & Exhibition CenterThe Company's lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC),...
2025-06-12 7:30 AM EDT
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December 2024, received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The product development plan is...
2025-06-09 7:30 AM EDT
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share. The warrants have an exercise price of $3.10 per share and will expire 5 years from the date of issuance. Maxim Group LLC...
2025-06-02 1:40 PM EDT
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants will have an exercise price of $3.10 per share and will expire 5 years from the date of issuance. Maxim Group LLC...
2025-05-29 8:30 PM EDT
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital...
2025-05-22 7:30 AM EDT
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention (AUR) and high CV risk Prostate CancerPhiladelphia, Pennsylvania--(Newsfile Corp. - April 28, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based late clinical-stage drug development company, announced today that they have entered into a binding letter of intent dated April 26, 2025 (the "Letter Agreement") pursuant to which Medicus has agreed to acquire all of the...
2025-04-28 7:30 AM EDT
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90).The Company to Expand the Study into Additional Trial Sites in EuropePhiladelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that Institutional Review Board (IRB) has approved the increase in number of patients from sixty (60) to Ninety (90). The phase 2 clinical study (SKNJCT-003) which is currently underway in...
2025-04-21 7:30 AM EDT
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - March 10, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share. The warrants have an exercise price of $2.80 per share and will expire 5 years from the date of issuance....
2025-03-10 4:05 PM EDT
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants will have an exercise price of $2.80 per share and will expire 5 years from the date of issuance. ...
2025-03-06 8:30 PM EST
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).The SKNJCT-003 clinical study is currently underway in nine (9) clinical sites in United States and is expected to randomize 60 patients. The interim analysis was conducted after more than 50% of the targeted 60 patients in the study...
2025-03-06 7:30 AM EST
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).Insights Research Organization and Solutions (IROS),...
2025-02-27 7:30 AM EST
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003), which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study. The Company also announced that it is on track to complete an interim data analysis before the end of Q1 2025 and...
2025-02-14 7:30 AM EST
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to US$15,000,000 of the Company's common shares (the "Shares") to the Investor at any...
2025-02-11 7:41 AM EST
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 12, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug (INAD File No.013880) has received Minor Use in Major Species Designation ("MUMS") from the U.S. Food and Drug Administration ("FDA") for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The company received a notification from the FDA on December 9th 2024.MUMS...
2024-12-12 7:30 AM EST
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 2, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region.Under the agreement, Swanielle, a bespoke healthcare consulting firm, will help identify a pharmaceutical/biotech company or companies in Southeast Asia to partner with Medicus to expand the Phase 2 clinical...
2024-12-02 7:30 AM EST
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 18, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer."We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on...
2024-11-18 7:30 AM EST
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants have an exercise price of US$4.64 per share and will expire 5 years from the...
2024-11-15 4:47 PM EST
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants will have an exercise price of US$4.64 per share and will expire 5 years from the date...
2024-11-13 6:45 PM EST
Medicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing
Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") today announced that it has completed a consolidation of its common shares on a 2-to-1 basis (the "Consolidation").The Company has completed the Consolidation in connection with its proposed U.S. initial public offering and application to list on a U.S. national securities exchange. For further details, please refer to the Company's news release dated May 29, 2024.The Company expects its common shares to...
2024-10-28 12:28 PM EDT